Phase 2 Lymphoma Trial, Recruiting (NCT04837859)

Phase 2 Lymphoma Trial, Recruiting NCT04837859 Sponsor: University of Cologne Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT04837859 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 to 60 years (main group), or aged 61 and older if a doctor determines they are suitable for a specific treatment combination called AVD based on an overall health assessment (exploratory group)
People who have recently been diagnosed with classical Hodgkin lymphoma (a type of blood cancer) for the first time and have not yet received any treatment for it
People whose disease is classified as early-stage but with certain risk features — specifically stage IA, IB, or IIA with at least one of the following: a large mass in the chest, cancer that has spread outside the lymph nodes, a raised inflammation marker in the blood, or cancer in three or more groups of lymph nodes; or stage IIB with a large chest mass or spread outside the lymph nodes

Who may not be able to join:

People whose lymphoma is a specific type called nodular lymphocyte-predominant Hodgkin lymphoma, or a type called grey-zone lymphoma
People whose lymphoma has spread to the brain or spinal cord

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Paul Broeckelmann, Dr., 1st Department of Medicine, Cologne Universit Hospital

Phone: +49221478

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04837859

Sponsor: University of Cologne

Phase: Phase 2

Status: Recruiting

Condition: Lymphoma

Trial contact: +49221478

More information: https://clinicaltrials.gov/study/NCT04837859

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 to 60 years (main group), or aged 61 and older if a doctor determines they are suitable for a specific treatment combination called AVD based on an overall health assessment (exploratory group)
People who have recently been diagnosed with classical Hodgkin lymphoma (a type of blood cancer) for the first time and have not yet received any treatment for it
People whose disease is classified as early-stage but with certain risk features — specifically stage IA, IB, or IIA with at least one of the following: a large mass in the chest, cancer that has spread outside the lymph nodes, a raised inflammation marker in the blood, or cancer in three or more groups of lymph nodes; or stage IIB with a large chest mass or spread outside the lymph nodes

Who may not be able to join:

People whose lymphoma is a specific type called nodular lymphocyte-predominant Hodgkin lymphoma, or a type called grey-zone lymphoma
People whose lymphoma has spread to the brain or spinal cord

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of Cologne

Registry

ClinicalTrials.gov

Start date

24 May 2024

Est. completion

1 May 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Progression Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov